Navigation Links
Gen-Probe to Webcast Two Upcoming Investor Presentations
Date:5/6/2009

- Bank of America and Merrill Lynch 2009 Health Care Conference on May 12 -

- Deutsche Bank 34th Annual Health Care Conference on May 19 -

SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will present at the Bank of America and Merrill Lynch 2009 Health Care Conference in New York on May 12, 2009 at approximately 9:20 a.m. Eastern time, and at the Deutsche Bank 34th Annual Health Care Conference in Boston on May 19, 2009 at approximately 10:10 a.m. Eastern time. The presentations are scheduled to be webcast live and may be accessed through a link on the investors section of Gen-Probe's website at www.gen-probe.com. The webcasts will be available for 30 days following the event.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,200 people. For more information, go to www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including our most recent Form 10-Q and all subsequent periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

    Contact:

    Paula Izidoro
    Investor Relations
    858-410-8904


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Gen-Probe Reports Financial Results for First Quarter 2009
2. Gen-Probe, Roche Prevail in Arbitration With Digene Concerning Human Papillomavirus Agreement
3. Gen-Probe Board of Directors Elects Carl Hull Chief Executive Officer
4. Tepnel Shareholders Approve Acquisition by Gen-Probe
5. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008
6. Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
7. Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
8. Eric Tardif Joins Gen-Probe as Senior Vice President, Corporate Strategy
9. Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
10. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
11. Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2017)... ... , ... Medical lab testing through hospitals and other traditional methods ... will take days to arrive to the end customer, having to travel through medical ... lab tests, bypassing the cost and delay of traditional means. Now all employees of ...
(Date:1/21/2017)... ... 2017 , ... Salveo for life, a company that distributes an effervescent lime-flavored ... States as part of its presence to expand its market reach. , Using a ... productions of nasty toxins as a result of drinking alcohol, eliminating those toxins quickly, ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... Seamild, the ... on the futuristic vision of its owner and founder. As Oat is recognized globally ... to everybody he knows personally as he believes it is a move to sow ...
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate Institute’s ... electrifying line-up of events for its annual meeting “Coming Home 2017,” an activity-packed ... “Coming Home 2017” will be held on Friday January 27 through Sunday, January ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa ... in Petaluma, located at 167 Lynch Creek Way. The Petaluma office features three ... medicine and rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 23, 2017  Therabron Therapeutics, Inc., a clinical-stage ... in respiratory care, today announced that the European ... has granted Orphan Drug Designation for Therabron,s CG367 ... Syndrome (BOS).  "We are pleased to ... to treat patients diagnosed with BOS following lung ...
(Date:1/23/2017)... , Jan. 23, 2017 LifeVac, the ... a blocked airway and prevented choking deaths, welcomes ... advocate to the LifeVac team as Official Spokesperson. ... join the LifeVac team," said Arthur Lih , ... to represent LifeVac and his mission to raise awareness ...
(Date:1/23/2017)... 23, 2017 Research and Markets has announced the ... - Product - Forecast to 2025" report to their offering. ... Report Highlights: ... trends to identify the investment opportunities Market forecasts till ... Key market trends across the business segments, Regions and Countries ...
Breaking Medicine Technology: